NDAORAL, RECTALPOWDERPriority Review
Approved
Jun 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
KAYEXALATE (sodium polystyrene sulfonate) by ANI Pharmaceuticals is potassium ion exchange activity [moa]. First approved in 1958.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KAYEXALATE (sodium polystyrene sulfonate) is an ion-exchange resin that removes excess potassium from the body by exchanging sodium ions in the gastrointestinal tract. It is indicated for the treatment of hyperkalemia (elevated serum potassium levels) across various patient populations. The drug works through a non-systemic potassium ion exchange mechanism, making it a foundational therapy in nephrology and critical care settings.
LOE Approaching
As a mature, off-patent product nearing exclusivity challenges, KAYEXALATE teams are focused on defending market share against generic and emerging alternatives rather than driving growth.
Mechanism of Action
Potassium Ion Exchange Activity
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KAYEXALATE currently shows zero linked job openings, reflecting its mature lifecycle stage and limited active development. Career opportunities on this product are primarily in defensive commercial and reimbursement roles focused on market maintenance and generic competition management.
Brand ManagerField Sales Representative
Worked on KAYEXALATE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.